Lyell Immunopharma is a late-stage clinical cell therapy company developing next-generation autologous CAR T-cell product candidates for cancer. Its lead candidate, rondecabtagene autoleucel (ronde-cel, formerly LYL314), is a dual-targeting CD19/CD20 CAR T-cell therapy in pivotal trials for relapsed or refractory large B-cell lymphoma. A second candidate, LYL273, targets GCC-expressing metastatic colorectal cancer. Lyell applies its Epi-R manufacturing protocol to produce T cells with greater durability and anti-tumor potency, and discontinued its earlier LYL797, LYL845 and LYL119 programs in 2024 to concentrate on these two.
Lyell is publicly traded
IPO'd on Jun 17, 2021
This company is no longer available on our private secondary market. Shares can be traded publicly under LYEL.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2018
Employees
51–200
Total Funding
$1.04B
4 rounds
Last Private Valuation
$2.7B
Mar 2020
Closed $50M second tranche of $100M private placement at $25.61/share, completing raise begun July 2025.
Fresh capital extends runway into Q3 2027, easing near-term liquidity pressure for secondary holders.
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $1.04B across 4 rounds
Last updated 09-23-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Mar 2020 | Series C | $493M | $2.7B *estimated | Not disclosed |
| Jul 2019 | Series AA | $205M | — | GSK |
| May 2019 | Series B | $162.1M | — | Not disclosed |
Lynn Seely, M.D.
President and Chief Executive Officer
Rick Klausner, M.D.
Founder & Chairman of the Board
Crystal Mackall, M.D.
Founder
Stan Riddell, M.D.
Founder
Gary Lee, Ph.D.
Chief Scientific Officer
Stephen Hill, M.B.A.
Chief Operating Officer
David Shook, M.D.
Chief Medical Officer
Smital Shah
Chief Financial and Business Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Juno Therapeutics
Developer of CAR-T cell therapies for hematologic malignancies; acquired by Bristol-Myers Squibb.
Kite Pharma
Commercial leader in CAR-T therapies for lymphoma and leukemia; acquired by Gilead Sciences.
Orca Bio
Cell therapy company developing allogeneic CAR-T treatments; partnership with Lyell for solid tumors.
Achilles Therapeutics
Cell therapy company developing personalized T-cell therapies for cancer.
Yes, Lyell is publicly traded under the ticker symbol LYEL on the NASDAQ. The company went public in Jun 17, 2021.
Lyell trades under the ticker symbol LYEL on the NASDAQ. It began trading in Jun 17, 2021.
Lyell (LYEL on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker LYEL to place an order.
Lyell went public in Jun 17, 2021 via ipo, with an offering valuation of approximately $2.7B. Lyell has traded on Nasdaq as LYEL since its initial public offering on June 17, 2021, which sold 25,000,000 shares at $17.00 apiece for gross proceeds of about $425 million. The company effected a 1-for-20 reverse stock split on May 30, 2025 to address Nasdaq's minimum bid price requirement, and remains listed. It completed a $100 million equity private placement in March 2026 to fund the two pivotal trials of its lead CAR T-cell candidate.
Lyell raised $1.04B across 4 disclosed funding rounds prior to its public listing.
Lyell was co-founded by Rick Klausner, M.D., Crystal Mackall, M.D., and Stan Riddell, M.D. in 2018.
Lyell is headquartered in South San Francisco, CA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.